{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:52:20Z","timestamp":1771001540006,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urology"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.urology.2009.06.072","type":"journal-article","created":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T10:33:47Z","timestamp":1255084427000},"page":"1318-1322","source":"Crossref","is-referenced-by-count":54,"title":["Silodosin in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia: A 9-Month, Open-label Extension Study"],"prefix":"10.1016","volume":"74","author":[{"given":"Leonard S.","family":"Marks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc C.","family":"Gittelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence A.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weining","family":"Volinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Hoel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2009.06.072_bib1","first-page":"S3","article-title":"Pathophysiology of lower urinary tract symptoms in the aging male population","volume":"7","author":"Lepor","year":"2005","journal-title":"Rev Urol."},{"key":"10.1016\/j.urology.2009.06.072_bib2","first-page":"181","article-title":"Alpha blockers for the treatment of benign prostatic hyperplasia","volume":"9","author":"Lepor","year":"2007","journal-title":"Rev Urol."},{"key":"10.1016\/j.urology.2009.06.072_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1442-2042.2007.01956.x","article-title":"Alpha1-adrenoceptor subtypes and lower urinary tract symptoms","volume":"15","author":"Schwinn","year":"2008","journal-title":"Int J Urol."},{"key":"10.1016\/j.urology.2009.06.072_bib4","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0026-895X(25)10156-9","article-title":"The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype","volume":"45","author":"Forray","year":"1994","journal-title":"Mol Pharmacol."},{"key":"10.1016\/j.urology.2009.06.072_bib5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0022-5347(05)67426-5","article-title":"Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature","volume":"164","author":"Murata","year":"2000","journal-title":"J Urol."},{"key":"10.1016\/j.urology.2009.06.072_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0014-2999(96)00589-4","article-title":"Effect of KMD-3213, an alpha 1A-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta","volume":"315","author":"Yamagishi","year":"1996","journal-title":"Eur J Pharmacol."},{"key":"10.1016\/j.urology.2009.06.072_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00345-002-0246-7","article-title":"Tamsulosin: an overview","volume":"19","author":"Chapple","year":"2002","journal-title":"World J Urol."},{"key":"10.1016\/j.urology.2009.06.072_bib8","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0026-895X(25)10243-5","article-title":"KMD-3213, a novel, potent, alpha 1A-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues","volume":"48","author":"Shibata","year":"1995","journal-title":"Mol Pharmacol."},{"key":"10.1016\/j.urology.2009.06.072_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0022-3565(24)29676-2","article-title":"In vivo demonstration of alpha(1A)-adrenoceptor subtype selectivity of KMD-3213 in rat tissues","volume":"296","author":"Yamada","year":"2001","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.urology.2009.06.072_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1442-2042.2001.00277.x","article-title":"Effect of KMD-3213, an alpha1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs","volume":"8","author":"Akiyama","year":"2001","journal-title":"Int J Urol."},{"key":"10.1016\/j.urology.2009.06.072_bib11","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.juro.2009.02.034","article-title":"Rapid efficacy of the highly selective \u03b11a-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies","volume":"181","author":"Marks","year":"2009","journal-title":"J Urol."},{"key":"10.1016\/j.urology.2009.06.072_bib12","first-page":"S22","article-title":"A comparison of varying alpha-blockers and other pharmacotherapy options for lower urinary tract symptoms","volume":"7","author":"Chapple","year":"2005","journal-title":"Rev Urol."},{"key":"10.1016\/j.urology.2009.06.072_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1464-410X.2005.05485.x","article-title":"Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists","volume":"95","author":"Milani","year":"2005","journal-title":"BJU Int."},{"key":"10.1016\/j.urology.2009.06.072_bib14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejphar.2007.11.003","article-title":"In vivo study on the effects of alpha1-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs","volume":"580","author":"Noguchi","year":"2008","journal-title":"Eur J Pharmacol."},{"key":"10.1016\/j.urology.2009.06.072_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.bjp.0707369","article-title":"Alpha1-adrenoceptors and ejaculatory function","volume":"152","author":"Michel","year":"2007","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.urology.2009.06.072_bib16","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0090-4295(00)01042-6","article-title":"Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia","volume":"57","author":"Narayan","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.urology.2009.06.072_bib17","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0090-4295(98)00127-7","article-title":"Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial","volume":"51","author":"Lepor","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.urology.2009.06.072_bib18","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0090-4295(98)00126-5","article-title":"Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia","volume":"51","author":"Lepor","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.urology.2009.06.072_bib19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1464-410X.2003.04309.x","article-title":"Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies","volume":"92","author":"Roehrborn","year":"2003","journal-title":"BJU Int."},{"key":"10.1016\/j.urology.2009.06.072_bib20","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.eururo.2007.03.034","article-title":"The long-term outcome of medical therapy for BPH","volume":"51","author":"Madersbacher","year":"2007","journal-title":"Eur Urol."},{"key":"10.1016\/j.urology.2009.06.072_bib21","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","article-title":"Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?","volume":"154","author":"Barry","year":"1995","journal-title":"J Urol."}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042950902189X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042950902189X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T17:07:15Z","timestamp":1739380035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009042950902189X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S009042950902189X"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2009.06.072","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}